Effect of the peroxisome proliferator-activated receptor-γ C161T polymorphism on lipid profile in Brazilian patients with Type 2 diabetes mellitus

[1]  Hideo Ayame,et al.  [The Da Qing IGT and Diabetes study]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[2]  D. Johns,et al.  Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. , 2004, Clinical chemistry.

[3]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[4]  Allan Vaag,et al.  Impact of two common polymorphisms in the PPARgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both? , 2003, Diabetes.

[5]  R. Paschke,et al.  Lack of association between peroxisome proliferator-activated receptor-gamma-2 gene variants and the occurrence of coronary heart disease in patients with diabetes mellitus. , 2002, European journal of endocrinology.

[6]  M. Hirata,et al.  Increasing the Sensitivity of Single-Strand Conformation Polymorphism Analysis of the LDLR Gene Mutations in Brazilian Patients with Familial Hypercholesterolemia , 2002, Clinical chemistry and laboratory medicine.

[7]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[8]  Y. Terauchi,et al.  The Mechanisms by Which Both Heterozygous Peroxisome Proliferator-activated Receptor γ (PPARγ) Deficiency and PPARγ Agonist Improve Insulin Resistance* , 2001, The Journal of Biological Chemistry.

[9]  J. Frohlich,et al.  The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). , 2001, Clinical biochemistry.

[10]  M. Breyer,et al.  Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. , 2001, Kidney international.

[11]  A. Astrup,et al.  Obesity : Preventing and managing the global epidemic , 2000 .

[12]  R. Evans,et al.  Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency , 2000 .

[13]  E. Bonora,et al.  Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. , 2000, Diabetes care.

[14]  S. O’Rahilly,et al.  Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.

[15]  Xing-li Wang,et al.  Peroxisome proliferator-activated receptor γ C161→T polymorphism and coronary artery disease , 1999 .

[16]  J. Auwerx.  PPARγ, the ultimate thrifty gene , 1999, Diabetologia.

[17]  J. Ranstam,et al.  Differences in treatment and metabolic abnormalities between normo- and hypertensive patients with type 2 diabetes: the Skaraborg Hypertension and Diabetes Project. , 1999, Diabetes, obesity & metabolism.

[18]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[19]  J. Auwerx,et al.  PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter , 1998 .

[20]  A. Pfeiffer,et al.  Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. , 1998, The New England journal of medicine.

[21]  M. Hirata,et al.  Optimized procedure for DNA isolation from fresh and cryopreserved clotted human blood useful in clinical molecular testing. , 1998, Clinical chemistry.

[22]  J. Ranstam,et al.  Risk factor clustering in patients with hypertension and non‐insulin‐dependent diabetes mellitus. The Skaraborg Hypertension Project , 1998, Journal of internal medicine.

[23]  J. Auwerx,et al.  A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. , 1998, Human molecular genetics.

[24]  J. Auwerx,et al.  The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.

[25]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[26]  J. Lehmann,et al.  The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones , 1996 .

[27]  X. Chen,et al.  Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Sempos Ct,et al.  Summary of the Second Report of the National Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993 .

[29]  S. Horwitz,et al.  Mechanism of action of taxol. , 1992, Trends in pharmacological sciences.

[30]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.